Quarterly rpt on consolidated results for the financial period ended 30 Sep 2021

IHH HEALTHCARE BERHAD

Financial Year End

31 Dec 2021

Quarter

3 Qtr

Quarterly report for the financial

30 Sep 2021

period ended

The figures

have not been audited

Attachments

IHH_Q3 2021 Quarterly Report.pdf

460.3 kB

IHH Q3 2021 Press Release 29.11.2021.PDF

747.1 kB

Default Currency Other Currency

Currency: Malaysian Ringgit (MYR)

SUMMARY OF KEY FINANCIAL INFORMATION

30 Sep 2021

INDIVIDUAL PERIOD

CUMULATIVE PERIOD

CURRENT

PRECEDING YEAR

CURRENT

PRECEDING

YEAR

CORRESPONDING

YEAR TO

YEAR

QUARTER

QUARTER

DATE

CORRESPONDING

PERIOD

30 Sep 2021

30 Sep 2020

30 Sep 2021

30 Sep 2020

$$'000

$$'000

$$'000

$$'000

1

Revenue

4,444,996

3,518,331

12,661,047

9,638,617

2

Profit/(loss) before

616,618

395,969

1,871,578

-93,420

tax

3

Profit/(loss) for the

675,658

309,186

1,654,629

-289,620

period

4

Profit/(loss)

550,000

309,952

1,408,927

-130,476

attributable to

ordinary equity

holders of the

parent

5

Basic

6.01

3.28

15.30

-2.26

earnings/(loss) per

share (Subunit)

6

Proposed/Declared

0.00

0.00

0.00

0.00

dividend per share

(Subunit)

AS AT END OF CURRENT

AS AT PRECEDING FINANCIAL

QUARTER

YEAR END

7 Net assets per

2.5700

2.4800

share attributable

to ordinary equity

holders of the

parent ($$)

Definition of Subunit:

In a currency system, there is usually a main unit (base) and subunit that is a fraction amount of the main unit. Example for the subunit as follows:

Country

Base Unit

Subunit

Malaysia

Ringgit

Sen

United States

Dollar

Cent

United Kingdom

Pound

Pence

Announcement Info

Company Name

IHH HEALTHCARE BERHAD

Stock Name

IHH

Date Announced

29 Nov 2021

Category

Financial Results

Reference Number

FRA-29112021-00086

IHH HEALTHCARE BERHAD

Registration No. 201001018208 (901914-V)

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT

30 SEPTEMBER 2021

IHH HEALTHCARE BERHAD

Registration No. 201001018208 (901914-V)

(Incorporated in Malaysia)

UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2021

3rd quarter ended

Financial period ended

Note 30 Sep 2021

30 Sep 2020

Variance

30 Sep 2021

30 Sep 2020

Variance

RM'000

RM'000

%

RM'000

RM'000

%

Revenue

1

Other operating income

2

Inventories and consumables

Purchased and contracted services

Staff costs

3

Depreciation and impairment of property, plant and equipment

4

Depreciation and impairment of right-of-use ("ROU") assets

5

Amortisation and impairment of intangible assets

Operating lease expenses

Other operating expenses

6

Finance income

7

Finance costs

7

Share of profits/(losses) of associates (net of tax)

8

Share of profits of joint ventures (net of tax)

9

Profit/(Loss) before tax

Income tax expense

10

Profit/(Loss) for the period

Other comprehensive income, net of tax

Items that are or may be reclassified subsequently

to profit or loss

Foreign currency translation differences from

foreign operations

11

Realisation of FCTR1 upon disposal of a joint venture

/substantive liquidation of a subsidiary and a joint venture

Hedge of net investments in foreign operations

11

Cash flow hedge

Cost of hedging reserve

Items that will not be reclassified subsequently to profit or loss

Remeasurement of defined benefit liabilities

Total comprehensive income for the period

Profit/(Loss) attributable to:

Owners of the Company

Non-controlling interests

Profit/(Loss) for the period

Total comprehensive income attributable to:

Owners of the Company

Non-controlling interests

Total comprehensive income for the period

Earnings per share (sen)

Basic

Diluted

NM: Not meaningful

Note:

1. Foreign currency translation reserve

4,444,996

3,518,331

26%

12,661,047

9,638,617

31%

135,111

295,814

-54%

536,312

559,901

-4%

(930,141)

(730,464)

-27%

(2,669,383)

(2,007,597)

-33%

(412,660)

(311,626)

-32%

(1,133,011)

(945,689)

-20%

(1,643,585)

(1,324,740)

-24%

(4,587,812)

(3,933,541)

-17%

(268,021)

(236,302)

-13%

(887,522)

(710,288)

-25%

(83,024)

(118,629)

30%

(238,177)

(294,192)

19%

(11,493)

(14,032)

18%

(35,660)

(45,318)

21%

(20,577)

(17,934)

-15%

(58,169)

(49,351)

-18%

(494,112)

(407,400)

-21%

(1,414,562)

(1,671,916)

15%

(18,973)

112,899

-117%

169,976

243,815

-30%

(86,768)

(375,581)

77%

(503,702)

(881,571)

43%

5,409

(241)

NM

23,740

1,750

NM

456

5,874

-92%

8,501

1,960

NM

616,618

395,969

56%

1,871,578

(93,420)

NM

59,040

(86,783)

168%

(216,949)

(196,200)

-11%

675,658

309,186

119%

1,654,629

(289,620)

NM

25,430

(306,521)

108%

3,626

(398,103)

101%

-

(193,403)

100%

22,148

(132,984)

117%

58,030

19,290

NM

97,300

(65,741)

NM

376

494

-24%

8,802

(8,614)

NM

(406)

301

NM

(36)

226

-116%

83,430

(479,839)

117%

131,840

(605,216)

122%

(310)

3,704

-108%

849

(869)

198%

NM

NM

758,778

(166,949)

1,787,318

(895,705)

550,000

309,952

77%

1,408,927

(130,476)

NM

125,658

(766)

NM

245,702

(159,144)

NM

675,658

309,186

119%

1,654,629

(289,620)

NM

619,891

(169,888)

NM

1,524,659

(659,591)

NM

138,887

2,939

NM

262,659

(236,114)

NM

758,778

(166,949)

NM

1,787,318

(895,705)

NM

6.01

3.28

83%

15.30

(2.26)

NM

6.01

3.28

83%

15.30

(2.26)

NM

1

IHH HEALTHCARE BERHAD

Registration No. 201001018208 (901914-V)

(Incorporated in Malaysia)

UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2021

SUPPLEMENTARY INFORMATION

Note

3rd quarter ended

Financial period ended

30 Sep 2021

30 Sep 2020

Variance

30 Sep 2021

30 Sep 2020

Variance

Profit attributable to owners of the Company,

RM'000

RM'000

%

RM'000

RM'000

%

excluding EIxi

354,592

238,361

49%

1,154,002

343,557

NM

Add back/(Less): Exceptional items ("EI")

Remeasurement to fair value of interest in a joint venturei

409

-

86,177

-

Impairment loss on goodwillii

5

-

2,089

-

(397,064)

Gain on disposal of a subsidiaryiii

-

-

-

13,188

Gain/(Loss) on disposal of joint venturesiv

-

(407)

139,053

(407)

Realisation of FCTR upon substantive liquidation of

a subsidiary and a joint venturev

5

-

193,403

-

132,984

Provision for loan taken by a joint venturevi

(2,564)

(866)

(2,564)

(3,307)

Impairment of assetsvii

(51,284)

-

(241,282)

-

Deferred tax assets previously not recognisedviii

248,196

-

248,196

-

Change in fair value of cross currency swapsix

6

(29,790)

91,093

125,193

187,309

Exchange gain/(loss) on net borrowingsx

6

31,600

(265,911)

(126,328)

(494,563)

196,567

19,401

228,445

(561,860)

Less: Tax effects on EI

(2,153)

38,565

284

64,912

Less: Non-controlling interests' share of EI

994

13,625

26,196

22,915

195,408

71,591

254,925

(474,033)

Profit/(Loss) attributable to owners of the Company

77%

NM

550,000

309,952

1,408,927

(130,476)

Earnings per share, excluding EIxi (sen)

Basic

3.78

2.46

54%

12.40

3.15

NM

Diluted

3.78

2.46

54%

12.39

3.14

NM

NM: Not meaningful

Note:

"Acibadem Holdings" as referred to throughout this financial report includes the wholly-owned Integrated Healthcare Turkey Yatirimlari Limited Group, which owns approximately 90% interest in Acıbadem Sağlık Yatırımları Holding A.Ş. Group.

  1. Remeasurement to fair value of interests in DDRC SRL Diagnostics Private Limited ("DDRC SRL"), upon acquisition of controlling interest in DDRC SRL
  2. Impairment of goodwill over Ravindranath GE Medical Associates Pte Ltd (also known as "Global Hospitals")
  3. Disposal of 70% interest in Famicord Acibadem Kordon Kani Saglik Hizmetleri Anonim Sirketi
  4. Disposal of joint ventures - Apollo Gleneagles Hospital Ltd, net of realisation of FCTR of RM22.1 million loss (2020: Shanghai Hui Xing Hospital Management Co., Ltd. and Shanghai Hui Xing Jinpu Co., Ltd. ("Shanghai Hui Xing Group"))
  5. Realisation of FCTR upon substantive liquidation of IHH (Bharat) Limited (a subsidiary) and Khubchandani Hospital (a joint venture)
  6. Provision for proportionate share of amounts owed by Khubchandani Hospitals on its loans, that is unlikely to be repaid
  7. Impairment of assets of Gleneagles Chengdu Hospital (the Group's hospital that was operational in late 2019 whose ramp up was longer than expected and was hampered by the COVID-19 pandemic) and Andaman Alliance Healthcare Limited ("AAHL") (the Group's greenfield hospital project in Myanmar which has stalled)
  8. Deferred tax assets previously not recognised by Acibadem Holdings
  9. Fair value changes of cross-currency swaps which were entered to hedge a portion of Acibadem Holdings' foreign currency denominated borrowings
  10. Exchange differences arising from foreign currency denominated borrowings/payables net of foreign currency denominated cash/receivables, recognised by Acibadem Holdings (As at 30 September 2021, Euro/TL=10.3135)
  11. Exceptional items, net of tax and non-controlling interests

The unaudited Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the 2020 Audited Financial Statements and the accompanying explanatory notes attached to this financial report.

2

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

IHH Healthcare Berhad published this content on 29 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 November 2021 10:49:02 UTC.